logo-loader
NASDAQ:TCON

TRACON Pharmaceuticals

Receive alerts
Market:
NASDAQ
Market Cap:
$12.65 m
Price
2.30 USD
Change
10.05%
52 weeks high
8.90
52 weeks low
0.95

In brief

TRACON (NASDAQ:TCON) is a U.S. biotech with a product development platform that offers corporate partners CRO-independent clinical development and U.S. commercialization expertise.  TRACON has in-licensed N. American rights to a subcutaneous PD-L1 antibody for sarcoma (12/19) expected to initiate a US registrational trial in 2020, a prostate cancer asset from J&J (2016) expected to have a P2 read-out in 2020, a CD73 antibody from I-Mab (2018) in a P1 trial and rights to multiple  bi-specific antibodies, one or more of which are expected to be IND ready in 2020. An antibody out-licensed to Santen is expected to have P2 data in 2020.

Deep dive We explore the investor case for growth companies

Snapshot

The San Diego company utilizes a capital-efficient product development platform to develop its clinical-stage pipeline of cancer therapies